DnB Asset Management AS Purchases 74,457 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

DnB Asset Management AS increased its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 116.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 138,665 shares of the company’s stock after acquiring an additional 74,457 shares during the period. DnB Asset Management AS’s holdings in Hims & Hers Health were worth $3,353,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $28,000. Raleigh Capital Management Inc. grew its holdings in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares in the last quarter. Blume Capital Management Inc. raised its holdings in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after purchasing an additional 1,413 shares during the period. Finally, US Bancorp DE boosted its stake in shares of Hims & Hers Health by 346.7% during the fourth quarter. US Bancorp DE now owns 1,943 shares of the company’s stock valued at $47,000 after purchasing an additional 1,508 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Michael Chi sold 7,259 shares of the firm’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $24.07, for a total transaction of $174,724.13. Following the sale, the insider now directly owns 193,601 shares of the company’s stock, valued at $4,659,976.07. This trade represents a 3.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Soleil Boughton sold 4,152 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the transaction, the insider now owns 157,345 shares of the company’s stock, valued at approximately $9,549,268.05. This represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,061,718 shares of company stock worth $37,894,395. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Price Performance

NYSE HIMS opened at $29.73 on Tuesday. The stock’s fifty day moving average price is $39.92 and its 200 day moving average price is $29.67. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98. The company has a market cap of $6.60 billion, a price-to-earnings ratio of 67.56 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. Research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Needham & Company LLC boosted their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Canaccord Genuity Group upped their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Bank of America lifted their target price on Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research note on Tuesday, March 18th. Leerink Partners boosted their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a report on Tuesday, February 25th. Finally, BTIG Research started coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $37.31.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.